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On March 24 and 25, 2017 researchers and clinicians from around the world met at 
Temple University in Philadelphia to discuss the current knowledge of Mycobacterium 
avium ssp. paratuberculosis (MAP) and its relationship to human disease. The confer-
ence was held because of shared concern that MAP is a zoonotic bacterium that poses 
a threat not only to animal health but also human health. In order to further study this 
problem, the conferees discussed ways to improve MAP diagnostic tests and discussed 
potential future anti-MAP clinical trials. The conference proceedings may be viewed on 
the www.Humanpara.org website. A summary of the salient work in this field is followed 
by recommendations from a majority of the conferees.
Keywords: Mycobacterium avium subspecies paratuberculosis, crohn’s disease, zoonosis and health public, 
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revieW OF tHe LiterAtUre AND cONcLUsiONs OF tHe 
cONFerees
Clinical and pathological similarities between the chronic regional inflammatory disease in humans 
and the disease in ruminants later called Johne’s disease (JD) were pointed out shortly after the cattle 
disease was described in 1895 (1). Its Mycobacterium avium spp. paratuberculosis (MAP) etiology 
was identified by Twort et al. in culture (2) and human pathological features described by Dalziel 
(3). The recovery of MAP following prolonged culture of ileal tissue from some patients with Crohn’s 
Disease (CD) (4), its identification by nucleic acid hybridization as MAP in the intestinal tissue of 
some patients with CD (5) and ability to culture viable MAP from peripheral blood monocytes and 
breast milk from CD patients all support the theory that MAP is a cause of CD (6, 7). In a blind study, 
three independent laboratories using Naser’s method have confirmed that viable MAP is found at a 
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higher prevalence in CD patients than in controls (8). This theory 
remains plausible and valid (9, 10).
Explanations for a cause of CD must account for a number 
of established observations: (a) two meta-analyses of the large 
number of studies have confirmed that MAP can be detected 
at a higher prevalence in patients with CD than in healthy 
controls (11, 12), (b) MAP has been cultured from peripheral 
blood mononuclear cells significantly more often in patients 
with CD than normal controls (6), and (c) open label (13, 14) 
and controlled clinical trials of antibiotic therapy of CD have 
shown a therapeutic benefit with ciprofloxacin, metronidazole, 
clarithromycin, rifamycin analogs, and clofazimine (15). In 
a recent confirmation of the MAP association with CD by 
another research group, Timms et al. used 3 PCR assays (IS900, 
f57, and nested IS900) and age- and sex-matched controls and 
also found a significant association of MAP and CD (p = 0.02) 
(16). Detection of MAP in non-CD patients is alarming since 
MAP has also been linked to several other chronic inflammatory 
syndromes (17).
The hypothesis that MAP is a cause of CD was dealt a blow 
when an Australian Trial (the Selby study) of anti-MAP antibiot-
ics in CD patients suggested no therapeutic benefit (18). However, 
an “intention-to-treat” re-analysis showed that the addition of 
combination antibiotics to standard of care therapy and steroids 
used in the trial performed significantly better than placebo plus 
standard of care therapy and steroids (19). The current interpreta-
tion of the Australian Trial is that the antimycobacterial therapy 
was beneficial in treating CD but was not curative. It is important 
to note that the doses used in the Australian trial were lower than 
the doses used in current clinical trials (RedHill Biopharma first 
FDA phase III trial NCT01951326).
Anecdotal case reports support a causal role for MAP in CD 
with antibiotic therapy producing long-term profound remission 
off any active therapy, which resembles cured CD. For example, 
in 2002, Hermon-Taylor described a patient with classic CD and 
a positive MAP ELISA test [one of the tests used to identify MAP 
infection in cattle (20)] The patient received antimycobacterial 
therapy (clarithromycin, rifabutin, and clofazimine) for 1.5 years 
and has remained without disease since 2001 (Hermon-Taylor J, 
Personal Communication, 2017). Additional cases of patients 
that were prospectively treated for MAP infection have also 
shown long-term profound remission/cures (21, 22) including 
one patient with a positive MAP blood culture that became 
negative along with resolution of lesions associated with CD 
(23). Similar reports have been published including resolution 
of disease in two patients, one with classic CD and the other 
with complex regional pain syndrome, following treatment for 
blood cultures positive for MAP with resolution of disease and 
blood cultures for MAP becoming negative (24). Eleven further 
CD patients with profound, clinical, and histological remission 
for 3–22 years off all therapy were presented at the conference 
(25). Such reports indicate that anti-MAP therapies are bringing 
us closer to approaching a cure (14). Singh et al. (26) described 
an Indian CD patient with stool culture positive for typical MAP 
colonies on HEY agar slants containing mycobactin J. Biotyping 
of the colonies with the IS1311 PCR-RE and IS1311 L2 PCR-REA 
demonstrated the bacterium was the “Indian Bison type,” of MAP, 
the predominant form of MAP in India (27). The patient’s serum 
was also positive for MAP antibodies by ELISA. Following 1 year 
of antibiotic therapy, the disease was suppressed and the organ-
ism could no longer be cultured from the stool.
Mycobacterium avium ssp. paratuberculosis, the organism 
proven to cause JD in ruminant animals and identical to the 
organism isolated in the previously described patients, has been 
cultured from pasteurized milk (28–30), from beef (31), and from 
commercial infant formula (32). By USDA estimates, the herd-
level prevalence of MAP infection in U.S. dairy herds has increased 
from 21.6% in 1996 to 91.1% in 2007 (33). The magnitude of the 
difference in prevalence over this period of time suggests that the 
change is unlikely due to sampling methods alone. During this 
same period, CD has increased in the US and now affects 201 per 
100,000 adults (34). Hospital stays for any-listed CD increased 
from >120,000 (44.2 per 100,000) in 2003 to >196,000 (59.7 per 
100,000) in 2013 (p < 0.05) (35).
Using a standard definition of consensus, which is the major-
ity opinion, the conference participants reached consensus on 
several issues relating to MAP. A majority of the conferees (78%) 
at the Temple University MAP conference concluded that the 
accumulating information now strongly supports the theory that 
MAP is a zoonotic bacterium while 22% were uncertain whether 
MAP causes human disease. A majority of the conferees (72%) 
noted that MAP present in dairy products and meat causes 
disease in some humans and thus poses a public health threat 
while 28% were uncertain whether MAP is a public health risk. 
In addition, to better understand the role of this organism in the 
human host, the conferees proposed the following future efforts.
To address concerns about the reproducibility and sensitivity 
of the different diagnostic methods currently used, the group 
agreed to undertake a cross-laboratory comparison of four differ-
ent already available blood culture methods (6, 36–38). The MAP 
blood culture test that performs best will then be compared to the 
intestinal tissue culture method (37). MAP isolates will undergo 
genetic sequencing and be compared to published MAP genomic 
data (39) to confirm identity.
A cross-laboratory comparison of the available diagnostic 
serologic MAP antibody tests will also be undertaken (40–43). 
The preceding studies will be performed with blinded samples 
from CD patients and from healthy controls obtained from 
multiple clinical sites.
The blood culture method could then be used to select patients 
for a study of a combination of antibiotics in CD patients. Suggested 
inclusion criteria for a clinical trial include an established CD 
diagnosis and two positive blood cultures separated by at least 
1 week. Additional cultures would be done during and after the 
study to test the association between the clinical response and 
MAP detection.
The antibiotic therapy that would be prescribed in the treat-
ment group remains to be finalized. As previously described, 
RedHill Biopharma is already conducting a US first FDA phase 
III clinical trial of a combination of clarithromycin, rifabutin, 
and clofazimine in CD patients. Instead of repeating the work of 
this groundbreaking study, other options should be considered 
for future clinical trials. Such possible options include: combina-
tions of clarithromycin, ethambutol, methotrexate, Vitamin D, 
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metronidazole, rifaximin, rifampicin, gentamicin, or amikacin 
(22, 44–49). Each combination requires preliminary “proof of 
concept” studies and the study authors will agree on the best 
choice at a later date, taking into account previous experience 
which has been reported in the literature.
Based on the results of the genome wide association studies 
linking CD with innate immune deficiency, other therapies that 
enhance immunity should be considered. It also was noted that 
gallium nitrate and monensin sodium have been proposed for use 
to treat JD and should be considered for possible human use (50).
A majority of the conferees concluded that current evidence 
strongly supports the theory that MAP causes CD in some geneti-
cally susceptible human hosts. While it is impossible and inap-
propriate to feed MAP to healthy human infants to test whether 
genetically predisposed individuals develop CD, such exposure 
to viable MAP in infant formula and milk occurs daily. The best 
proof of causation is still Koch’s and later Relman’s postulates, 
which have now been satisfied for MAP in CD (51, 52). Ideally, 
reliably curing the disease with anti-MAP therapy, and linking 
profound remission/cure to the posttreatment absence of the 
MAP organism in the human host would be very supportive. This 
latter step has been accomplished in the small number of patients 
as described in the preceding references. Controlled clinical tri-
als will only prove or disprove that a particular therapy is better 
than the control placebo or an alternate therapy. Nevertheless, 
even today, the precautionary principle (53) should apply for the 
protection of the public health.
A majority of the conferees request that the appropriate gov-
ernmental agencies (NIH, FDA, USDA and the CDC, and their 
counterparts in other nations) review all available literature on 
JD (in cattle) and CD (in humans) that supports that these two 
diseases have a shared etiology (MAP) and consider epidemiologic 
studies (including available data from other countries including 
Italy, India, China, Israel, Japan, and Bahrain) (54) to explore this 
association further, using the Mini Sentinel and/or other databases.
A majority of the conferees strongly urge that the possibility that 
MAP causes human disease no longer be ignored. Should further 
compelling evidence become available, it is recommended that the 
FDA and USDA (and their counterparts in other nations) have 
contingency plans in place to rapidly eliminate MAP from the milk 
and meat supply through effective MAP control measures including 
biosecurity and hygiene, vaccination, and test-and-cull programs 
(20). Even if public health measures are not put in place by the 
appropriate regulatory agencies, food producers are encouraged 
to offer food products from animals in MAP control programs. 
Many food producers are already undertaking voluntary control 
practices (55) and this effort is encouraged and commended. The 
international representation in the authorship of this article attests 
to the observation that CD is now a worldwide epidemic.
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